Latest Isis Stories
CARLSBAD, Calif., Nov. 2, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes. Isis will develop both ISIS-GCGRRx and ISIS-GCCRRx to treat a broad population of diabetic patients. The unique mechanism of action of these new drugs could allow each drug to be used in combination with other therapies for type 2...
PROVIDENCE, R.I., Oct. 12, 2011 /PRNewswire/ -- Isis Biopolymer announced the appointment of Chris Hobson as its new president and chief executive officer, effective October 1, 2011. Concurrently, Mr. Hobson has been appointed to the Isis Biopolymer board of directors. Isis Biopolymer, based in Providence, RI, has pioneered advancements in polymer chemistry, miniaturization and electronics packaging to provide "active" transdermal infusion technology for the next generation delivery of...
CARLSBAD, Calif., Oct. 11, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has designated the second development candidate, ISIS-AATRx, in its collaboration with GlaxoSmithKline (NYSE: GSK). Isis earned a $5 million milestone payment from GSK for the selection of ISIS-AATRx. ISIS-AATRx is an antisense drug designed to treat liver disease caused by alpha-1 antitrypsin deficiency, or AATD, by inhibiting the production of an abnormal protein, which...
CARLSBAD, Calif., Sept. 23, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has filed a patent infringement lawsuit against Santaris Pharma A/S and Santaris Pharma A/S Corp. in the United States District Court of the Southern District of California. Isis' infringement suit against Santaris is based upon Santaris' activities providing antisense drugs and antisense drug discovery services to several pharmaceutical companies. As alleged in the complaint,...
SAN DIEGO, Sept. 20, 2011 /PRNewswire/ -- Civic leaders today joined senior management from Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and BioMed Realty Trust, Inc. (NYSE: BMR) to celebrate the completion of a new 176,000 square foot build-to-suit corporate and research facility on Gazelle Court in the Carlsbad Oaks North Business Park in Carlsbad. Among the featured speakers at the ceremony were Stanley T. Crooke, M.D., Ph.D., Chairman and Chief Executive Officer, and B. Lynne Parshall,...
NEW YORK, Sept. 16, 2011 /PRNewswire-USNewswire/ -- On the September 14th season premiere of Tyra Banks' hit show America's Next Top Model, transgender contestant Isis King returned as a fan favorite. Isis got her start on the show posing as a model for a Cycle 5 episode focused on youth homelessness. On the next season, she returned as a fierce contestant, despite the physical challenges of modeling as a transgender female, prior to her gender reassignment surgery. Founded by Taz Tagore...
NEW YORK, Sept. 13, 2011 /PRNewswire/ -- Isis Venture Partners, through its operating subsidiary Latin Trade Group, announced today that it had acquired a majority interest in Datarisk. Based in Buenos Aires, Datarisk is a leading provider of risk mitigation and commercial assurance solutions to major corporations operating regionally in Latin America (www.datariskglobal.com). "As Latin America becomes an increasingly important trade and investment hub, Datarisk's services will be in high...
CARLSBAD, Calif., Sept. 13, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at UBS' Global Life Sciences Conference on Monday, September 19, 2011 at 1:30 p.m. ET at the Grand Hyatt New York. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be...
CARLSBAD, Calif., Sept. 6, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast: Data from Mipomersen's Open-Label Extension Study What: presented at ESC Wednesday, September 07, 2011 at 12:00 p.m. ET /9:00 When: a.m. PT Where: www.isispharm.com Live on the Internet. Simply log onto our Web site How: listed above. If you are...
CARLSBAD, Calif., Sept. 1, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Stifel Nicolaus' Healthcare Conference 2011 on Thursday, September 08, 2011 at 2:05 p.m. ET at the Four Seasons Hotel in Boston. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the...
